List of Excipients in Branded Drug JANUMET XR

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
A-S Medication Solutions	JANUMET XR	sitagliptin and metformin hydrochloride	50090-6244	ALUMINUM OXIDE
A-S Medication Solutions	JANUMET XR	sitagliptin and metformin hydrochloride	50090-6244	CARNAUBA WAX
A-S Medication Solutions	JANUMET XR	sitagliptin and metformin hydrochloride	50090-6244	FD&C BLUE NO. 2
A-S Medication Solutions	JANUMET XR	sitagliptin and metformin hydrochloride	50090-6244	HYDROXYPROPYL CELLULOSE
A-S Medication Solutions	JANUMET XR	sitagliptin and metformin hydrochloride	50090-6244	HYPROMELLOSE 2208
A-S Medication Solutions	JANUMET XR	sitagliptin and metformin hydrochloride	50090-6244	HYPROMELLOSE 2910

Janumet XR Excipient Strategy and Commercial Opportunities

Last updated: August 19, 2026

Janumet XR is a once-daily fixed-dose combination of sitagliptin phosphate and extended-release metformin hydrochloride. Its commercial value comes from reducing pill burden while managing the formulation challenges of a high-dose, extended-release metformin tablet. The strongest excipient opportunities are in controlled-release polymers, tablet-processability aids, coating systems, impurity control, and cost-optimized generic formulations.

What is Janumet XR and how does its formulation work?

Janumet XR combines:

Component	Function	Formulation relevance
Sitagliptin phosphate	DPP-4 inhibitor	Low-dose, immediate pharmacologic component
Metformin hydrochloride	Biguanide antihyperglycemic	High-dose component requiring extended release
Hydrophilic matrix excipients	Control metformin release	Must provide reproducible dissolution across strengths
Binders and fillers	Support tablet hardness and uniformity	Important because metformin hydrochloride has a high drug load
Lubricants and glidants	Improve compression and manufacturability	Must not impair matrix hydration or dissolution
Film-coating system	Protects and identifies the tablet	Controls appearance, swallowability and handling

Janumet XR is approved in multiple dose combinations, including sitagliptin/metformin XR strengths of 50/500 mg, 50/1,000 mg and 100/1,000 mg, according to the U.S. prescribing information. The product is administered once daily with meals. The high metformin content creates the principal excipient and manufacturing constraint (Merck, 2024).

The formulation has to deliver sitagliptin exposure comparable to the immediate-release fixed-dose product while extending metformin release over the dosing interval. It also must limit dose dumping, control gastrointestinal exposure and maintain tablet integrity during compression, packaging and storage.

What excipients are used in Janumet XR?

The U.S. prescribing information identifies inactive ingredients that include matrix-forming and processing excipients such as hypromellose, microcrystalline cellulose, povidone, sodium stearyl fumarate and colloidal silicon dioxide. The film coating contains conventional components including polyvinyl alcohol, polyethylene glycol, talc and titanium dioxide. Iron oxides are used for color differentiation in certain strengths (Merck, 2024).

The exact excipient composition can vary by strength and manufacturing configuration. The commercial formulation strategy can be divided into four functional groups.

Controlled-release matrix excipients

Hypromellose is the central commercial opportunity. A high-viscosity hypromellose grade can form a hydrated gel layer that slows metformin diffusion and erosion. Polymer selection affects:

• Initial burst release
• Twelve- to twenty-four-hour dissolution profile
• Sensitivity to tablet hardness
• Food-effect behavior
• Scale-up reproducibility
• Risk of dose dumping

Alternative polymers include hydroxypropyl cellulose, polyethylene oxide and combinations of hydrophilic and hydrophobic matrix materials. Substitution is commercially attractive but regulatory risk is material because a polymer change can alter the entire dissolution profile.

High-load fillers and compression aids

Metformin hydrochloride occupies a large proportion of the tablet mass. Microcrystalline cellulose can improve compactibility and reduce capping, but excessive use can increase tablet size. Anhydrous dibasic calcium phosphate, lactose-based fillers and spray-dried mannitol may improve flow or hardness, but each introduces different water, density and dissolution behavior.

The best opportunity is not necessarily a novel excipient. It is often a lower-cost, directly compressible grade that maintains:

• Content uniformity for sitagliptin
• Tensile strength at high drug load
• Low friability
• Acceptable tablet dimensions
• Equivalent dissolution under FDA conditions

Lubricants and glidants

Sodium stearyl fumarate and magnesium stearate can improve ejection and reduce sticking. Over-lubrication with magnesium stearate may create hydrophobic surfaces that delay matrix hydration and shift metformin release. Lubricant concentration, mixing time and shear are therefore critical process variables.

Colloidal silicon dioxide supports flow and reduces segregation. Its level must be controlled because changes in surface area and moisture can affect blend behavior, especially when a low-dose sitagliptin component is combined with a high-dose metformin component.

Film-coating systems

Film coatings provide color coding, swallowability and protection from handling damage. Polyvinyl alcohol-based coatings are widely used because they provide efficient coverage and predictable drying. Polyethylene glycol acts as a plasticizer, while talc reduces tack.

Commercial opportunities include lower-weight coatings, faster coating cycles, aqueous systems with reduced energy consumption and pigment systems that improve strength differentiation among dose levels. Coating changes generally carry less dissolution risk than matrix changes, but they can still affect moisture ingress and stability.

Which excipient attributes control Janumet XR performance?

The critical quality attributes are linked to excipient variability rather than only to nominal excipient identity.

Excipient attribute	Potential impact on Janumet XR
Hypromellose viscosity	Controls gel strength and metformin release
Particle-size distribution	Affects blend uniformity, compression and dissolution
Moisture content	Changes granulation, hardness and polymer hydration
Bulk density	Influences tablet size and die fill
Surface area	Affects flow and lubricant demand
Substitution pattern of cellulose ether	Changes hydration and erosion
Lubricant specific surface area	Alters ejection and release behavior
Coating solids and plasticizer ratio	Affects film integrity and moisture protection
Excipient impurities	Can affect stability and analytical methods

For a generic or reformulated product, excipient equivalence should be assessed functionally. A different hypromellose supplier may use the same compendial name but produce a different viscosity profile, particle morphology or hydration rate.

What excipient strategy is best for a generic Janumet XR?

A generic strategy should begin with the reference product’s dissolution behavior and manufacturing profile, not with a direct copy of the inactive-ingredient list. FDA guidance permits formulation differences in many ANDA settings, but the applicant must demonstrate pharmaceutical equivalence, bioequivalence and adequate product quality (FDA, 2015).

A practical formulation strategy has five stages:

1. Map the reference dissolution profile. Test multiple pH conditions, agitation speeds and food-related conditions.
2. Identify the release mechanism. Determine whether release is driven primarily by polymer swelling, erosion, diffusion or a combination.
3. Screen polymer grades. Evaluate viscosity, particle size and substitution pattern rather than only polymer name.
4. Optimize high-dose compression. Establish design space for granulation, lubrication, compression force and dwell time.
5. Link dissolution to pharmacokinetics. Use discriminatory dissolution methods to reduce the risk of an apparently acceptable batch failing in vivo.

The lowest-risk generic formulation is usually one that preserves the functional architecture of the reference product while reducing supplier cost, improving manufacturing throughput or simplifying the excipient package.

What formulations are protected by Janumet XR intellectual property?

Janumet XR intellectual property has historically covered the combination of sitagliptin and metformin, extended-release dosage forms, dosing regimens and pharmaceutical compositions. Relevant claims may cover:

• Sitagliptin/metformin fixed-dose combinations
• Once-daily administration
• Extended-release metformin with immediate-release sitagliptin
• Specific dissolution or pharmacokinetic profiles
• Bilayer or multilayer tablet configurations
• Salt forms and crystalline forms
• Manufacturing processes and tablet architectures

The commercial importance of formulation patents depends on whether they remain unexpired, are listed in the FDA Orange Book and can be designed around. A generic applicant may avoid a formulation claim through a different polymer system, release architecture or manufacturing process. That strategy still requires an assessment of infringement risk in each jurisdiction.

The Orange Book remains the controlling public source for listed U.S. patents and regulatory exclusivities. Patent status can change through expiry, pediatric extensions, terminal disclaimers, litigation outcomes or listing corrections (FDA, 2024a).

When does Janumet XR lose exclusivity?

Janumet XR does not have biologic exclusivity and is not subject to the biosimilar pathway. It is a small-molecule combination product eligible for abbreviated new drug applications.

The relevant loss-of-exclusivity analysis has four layers:

Exclusivity layer	Relevance to Janumet XR
NCE exclusivity	Applies to a new active ingredient, not generally to a later combination product if the actives previously had approval
Five-year orphan exclusivity	Not the primary protection for this diabetes product
Pediatric exclusivity	May extend listed patents or exclusivities by six months if granted
Listed patents	Primary barrier for ANDA applicants

The practical generic-entry date is the later of relevant patent expiry, settlement-based entry dates, regulatory exclusivity expiration and any enforceable court injunction. Janumet XR’s commercial exposure should therefore be evaluated from the current Orange Book listing and litigation docket, not from the original product approval date alone.

FDA approved Janumet XR in 2012 as a once-daily extended-release formulation of sitagliptin and metformin. The product’s current competitive risk is driven by patent and ANDA status rather than by a pending regulatory exclusivity period (FDA, 2012).

Which companies are challenging Janumet XR?

The principal challengers are generic-drug manufacturers that file ANDAs with Paragraph IV certifications against listed patents. Public FDA records and Orange Book data should be used to identify each applicant, dosage strength and certification status.

A Paragraph IV filing can trigger patent litigation if the patent holder files suit within the statutory period. The resulting 30-month stay may delay approval, although it does not automatically prevent a later launch if the applicant prevails, settles for an agreed entry date or obtains approval after the stay expires.

For business planning, challenger analysis should track:

• ANDA sponsor
• Strength covered
• Paragraph IV certification date
• Patent numbers challenged
• Litigation filing date
• District court venue
• Hatch-Waxman stay status
• Tentative approval date
• Settlement or license terms
• Authorized-generic rights

The strongest commercial threat normally comes from an applicant with a complete three-strength portfolio. A single-strength ANDA may have limited impact if physicians and payers continue to favor the full Janumet XR range.

What is the biosimilar risk for Janumet XR?

There is no biosimilar risk in the legal sense because sitagliptin/metformin is a small-molecule drug. The relevant competitors are:

• ANDA-approved generics
• Separate sitagliptin and metformin products
• Metformin extended-release products
• Other DPP-4 inhibitor/metformin combinations
• SGLT2 inhibitor/metformin combinations
• GLP-1-based diabetes therapies

The larger commercial threat is therapeutic substitution. A generic Janumet XR competitor can erode price directly, while SGLT2 and GLP-1 products can reduce the treated population for DPP-4 inhibitor combinations.

What commercial opportunities exist for excipient suppliers?

Excipient suppliers have four primary opportunities.

Polymer-grade differentiation

Suppliers can compete with high-viscosity hypromellose, polyethylene oxide and hybrid matrix systems that deliver equivalent release with lower polymer loading. Performance data under fed and fasted conditions are more valuable than compendial identity alone.

Direct-compression platforms

A co-processed filler-binder designed for high-dose, poorly compactable drugs can reduce granulation steps and improve throughput. The opportunity is strongest where the formulation can maintain metformin release without wet granulation variability.

Low-moisture processing

Moisture-controlled excipients can support stability and reduce process variation. This is relevant where the active ingredients, polymer or coating system are sensitive to water activity.

Regulatory support

Excipient suppliers that provide full quality packages have a commercial advantage. Useful data include:

• DMF or Type IV support
• Residual solvent profile
• Elemental impurity data
• Nitrosamine risk assessment
• Microbial limits
• Extractables and leachables information
• Lot-to-lot viscosity data
• Stability under ICH conditions

FDA’s increased focus on nitrosamines and supply-chain controls makes impurity documentation a selling point for both innovators and generic manufacturers (FDA, 2024b).

What manufacturing and IP barriers affect generic entry?

The principal barriers are technical and legal.

Technical barriers include reproducing metformin release across strengths, avoiding dose dumping, controlling sitagliptin uniformity and achieving bioequivalence with a large tablet. Manufacturing barriers include high-speed compression, sticking, capping, coating defects and segregation.

IP barriers include formulation claims, combination claims, method-of-use claims and process patents. A noninfringing formulation may still face litigation if the patent holder asserts broad composition or use claims. Conversely, a formulation patent that is difficult to enforce may have limited practical value if a generic can obtain approval with a distinct release mechanism.

How strong is the Janumet XR patent estate?

The estate is strongest where claims are directed to the specific extended-release combination architecture and supported by measurable dissolution or pharmacokinetic limitations. Broad claims covering the mere coadministration of sitagliptin and metformin are more vulnerable to validity and obviousness challenges because both active ingredients and their diabetes uses were known before the XR product.

Patent strength should be scored against:

1. Remaining patent term
2. Claim breadth
3. Orange Book listing status
4. Prior-art exposure
5. Ease of formulation design-around
6. Litigation history
7. Settlement restrictions
8. Commercial value of each dosage strength

An estate with several overlapping formulation patents can delay entry even when individual claims appear narrow. Its value declines sharply after the first credible ANDA challenge or after an authorized generic becomes commercially available.

Key Takeaways

• Janumet XR’s central formulation problem is controlled release of high-dose metformin while preserving sitagliptin performance.
• Hypromellose, filler-binder systems, lubricants and coating materials are the main excipient value pools.
• Functional equivalence matters more than matching the inactive-ingredient list.
• Generic development depends on discriminatory dissolution, high-dose compression control and bioequivalence.
• Janumet XR is exposed to ANDA competition, not biosimilars.
• Orange Book patents, Paragraph IV filings and settlement agreements determine practical entry timing.
• Excipient suppliers can differentiate through polymer performance, direct compression, impurity control and regulatory documentation.
• The most valuable IP claims are those tied to specific release architecture, dissolution behavior or manufacturing constraints.

FAQs

Can Janumet XR be reformulated with a different hypromellose grade?

Yes. A different hypromellose grade may be used if the formulation meets pharmaceutical equivalence, dissolution and bioequivalence requirements. Viscosity, particle size, substitution pattern and hydration behavior must be evaluated.

Is metformin hydrochloride compatible with direct compression in Janumet XR?

It can be, but the high dose creates flow, compressibility and tablet-size constraints. Co-processed excipients or dry granulation may improve manufacturability while preserving release performance.

Does changing the Janumet XR film coating create a new product?

Usually not by itself. A coating change may support a formulation variation or generic product, but its regulatory treatment depends on the scope of the change and its effect on stability, dissolution, appearance and identification.

Can a generic Janumet XR use a different release mechanism?

Potentially. A different matrix or multilayer architecture may be acceptable if it produces equivalent quality, performance and exposure. The change can increase both development cost and patent-design-around risk.

Are sitagliptin and metformin available as separate generic products?

Metformin has long been available generically. Sitagliptin generic availability depends on applicable U.S. patent, regulatory and launch conditions. Separate products can compete with Janumet XR through substitution but do not always provide the same adherence and convenience profile.

References

1. U.S. Food and Drug Administration. (2012). Janumet XR approval letter and prescribing information.
2. U.S. Food and Drug Administration. (2015). Draft guidance on metformin hydrochloride; sitagliptin phosphate tablets.
3. U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Food and Drug Administration. (2024b). Control of nitrosamine impurities in human drugs.
5. Merck & Co., Inc. (2024). Janumet XR: U.S. prescribing information.